ATE197454T1 - Isoxazol- und isothiazolverbindungen, die die kognitiven funktionen verbesseren - Google Patents

Isoxazol- und isothiazolverbindungen, die die kognitiven funktionen verbesseren

Info

Publication number
ATE197454T1
ATE197454T1 AT92912971T AT92912971T ATE197454T1 AT E197454 T1 ATE197454 T1 AT E197454T1 AT 92912971 T AT92912971 T AT 92912971T AT 92912971 T AT92912971 T AT 92912971T AT E197454 T1 ATE197454 T1 AT E197454T1
Authority
AT
Austria
Prior art keywords
isoxazole
cognitive functions
improve cognitive
treatment
isothiazole compounds
Prior art date
Application number
AT92912971T
Other languages
English (en)
Inventor
David S Garvey
George M Carrera Jr
Stephen P Arneric
Youe-Kong Shue
Nan-Horng Lin
Yun He
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE197454T1 publication Critical patent/ATE197454T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT92912971T 1991-05-29 1992-05-28 Isoxazol- und isothiazolverbindungen, die die kognitiven funktionen verbesseren ATE197454T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70692091A 1991-05-29 1991-05-29
PCT/US1992/004631 WO1992021339A1 (en) 1991-05-29 1992-05-28 Isoxazole and isothiazole compounds that enhance cognitive function

Publications (1)

Publication Number Publication Date
ATE197454T1 true ATE197454T1 (de) 2000-11-11

Family

ID=24839628

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92912971T ATE197454T1 (de) 1991-05-29 1992-05-28 Isoxazol- und isothiazolverbindungen, die die kognitiven funktionen verbesseren

Country Status (13)

Country Link
US (1) US5409946A (de)
EP (1) EP0588917B1 (de)
JP (1) JP3153551B2 (de)
AT (1) ATE197454T1 (de)
BR (1) BR1100981A (de)
CA (1) CA2109585C (de)
DE (1) DE69231557T2 (de)
DK (1) DK0588917T3 (de)
ES (1) ES2153360T3 (de)
GR (1) GR3035285T3 (de)
IE (1) IE921690A1 (de)
PT (1) PT100525B (de)
WO (1) WO1992021339A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010145A1 (en) * 1992-10-23 1994-05-11 Merck Sharp & Dohme Limited Dopamine receptor subtype ligands
US5424444A (en) * 1992-11-25 1995-06-13 Abbott Laboratories Method of preparing enantiomerically-pure 3-methyl-5-(1-alkyl-2(S)-pyrrolidinyl) isoxazoles
US5494680A (en) * 1993-12-08 1996-02-27 Minnesota Mining And Manufacturing Company Transdermal delivery device
US5677459A (en) * 1994-11-10 1997-10-14 Sibia Neurosciences, Inc. Methods for the preparation of modulators of acetylcholine receptors
US5705512A (en) * 1994-11-10 1998-01-06 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5723477A (en) * 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5594011A (en) * 1994-11-10 1997-01-14 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5703100A (en) * 1994-11-10 1997-12-30 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5824692A (en) * 1995-01-06 1998-10-20 Lippiello; Patrick Michael Pharmaceutical compositions for prevention and treatment of central nervous system disorders
DE19501022C1 (de) * 1995-01-14 1996-06-05 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Verabreichung von (s)-3-Methyl-5-(1-methyl-2-pyrrolidenyl)-isoxazol oder einem seiner pharmazeutisch akzeptablen Salze und Verfahren zu seiner Herstellung
WO1996030372A1 (fr) * 1995-03-24 1996-10-03 Japan Tobacco Inc. Derives diazabicyclo[3.3.1]nonane et leurs intermediaires, leur application therapeutique et procedes de production
US6194581B1 (en) 1995-04-07 2001-02-27 Merck & Co., Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
US5794887A (en) 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
US5723414A (en) * 1996-01-24 1998-03-03 Rohm And Haas Company 5-aryl-isoxazolinones and herbicidal use thereof
ES2318856T4 (es) 1996-04-23 2010-03-03 Targacept, Inc. Composiciones farmaceuticas para la prevencion y el tratamiento de trastornos del sistema nervioso central.
US5706829A (en) * 1996-06-06 1998-01-13 Creighton University Method for treating neurocardiogenic syncope
US5760049A (en) * 1997-02-21 1998-06-02 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
US6166032A (en) * 1997-02-07 2000-12-26 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
CA2289570C (en) 1997-05-30 2007-04-03 Neurosearch A/S 9-azabicyclo(3.3.1)non-2-ene and nonane derivatives as cholinergic ligands at nicotinic ach receptors
CA2289574C (en) 1997-05-30 2007-04-24 Neurosearch A/S 8-azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors
ZA984638B (en) 1997-05-30 1998-12-11 Neurosearch As Azacyclooctane and heptane derivatives their preparation and use
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6133002A (en) 1997-09-25 2000-10-17 Dsm N.V. Process for preparing optically active 2-amino-ω-oxoalkanoic acid derivatives
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
ES2425114T3 (es) * 2000-03-16 2013-10-11 The Mclean Hospital Corporation CDP-colina y uridina para el tratamiento del abuso del acohol
EP1565055B1 (de) * 2002-11-08 2013-06-12 THE McLEAN HOSPITAL CORPORATION Verbindungen für die Behandlung von Tabakabhängigkeit und -entwöhnung
BR0317586A (pt) * 2002-12-20 2005-11-22 Mclean Hospital Corp Compostos para normalização do ciclo sono/vigìlia
US20050113449A1 (en) * 2003-10-08 2005-05-26 Renshaw Perry F. Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
CA2542023A1 (en) * 2003-10-08 2005-09-22 The Mclean Hospital Corporation Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
PL1678172T3 (pl) 2003-10-15 2010-05-31 Targacept Inc Związki azabicykliczne do łagodzenia bólu oraz leczenia zaburzeń centralnego układu nerwowego
FR2862647B1 (fr) * 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
WO2005122767A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
EP1765364A4 (de) * 2004-06-10 2010-09-22 Mclean Hospital Corp Pyrimidine, wie z:b: cytidin, bei der behandlung von patienten mit bipolaren störungen
EP1784199A4 (de) * 2004-08-11 2010-06-23 Mclean Hospital Corp Verbindungen zur behandlung von marihuana-abhängigkeit, entzug und konsum
US7780981B2 (en) 2004-09-13 2010-08-24 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
KR20110075044A (ko) 2007-04-02 2011-07-05 파킨슨즈 인스티튜트 처치 치료의 부작용을 감소시키기 위한 방법 및 조성물
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
CA2736871C (en) * 2008-09-11 2019-03-12 Catholic Healthcare West Nicotinic attenuation of cns inflammation and autoimmunity
EP2523944A4 (de) 2010-01-11 2013-06-19 Mithridion Inc Verbindungen und zusammensetzungen für verbesserte wahrnehmung, herstellungsverfahren und behandlungsverfahren
WO2012033956A1 (en) 2010-09-08 2012-03-15 Mithridion, Inc. Cognition enhancing compounds and compositions, methods of making, and methods of treating
CN105026369A (zh) 2013-02-28 2015-11-04 德米拉股份有限公司 格隆铵盐
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
CA2974324A1 (en) 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems

Also Published As

Publication number Publication date
WO1992021339A1 (en) 1992-12-10
DK0588917T3 (da) 2001-02-12
IE921690A1 (en) 1992-12-02
CA2109585C (en) 2000-02-15
EP0588917A1 (de) 1994-03-30
EP0588917B1 (de) 2000-11-08
EP0588917A4 (de) 1994-04-13
US5409946A (en) 1995-04-25
BR1100981A (pt) 2000-04-18
PT100525B (pt) 1999-10-29
DE69231557T2 (de) 2001-06-21
ES2153360T3 (es) 2001-03-01
CA2109585A1 (en) 1992-12-10
GR3035285T3 (en) 2001-04-30
JP3153551B2 (ja) 2001-04-09
PT100525A (pt) 1993-09-30
JPH06508143A (ja) 1994-09-14
DE69231557D1 (de) 2000-12-14

Similar Documents

Publication Publication Date Title
DE69231557D1 (de) Isoxazol- und isothiazolverbindungen, die die kognitiven funktionen verbesseren
DK0663912T3 (da) Heterocykliske etherforbindelser til forstærkning af den kognitive funktion
FI931888A0 (fi) Kramploesande cykliska fruktopyranossulfiter -och sulfater
KR950702829A (ko) 신경계 퇴행성 질환의 치료에 유용한 아나바세인 유도체
DE69201956T2 (de) Pyrrolidin- und thiazolidinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
TNSN99169A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
FI980862A (fi) Kiraalisia metyylifenyylioksatsolidinoneja
GEP20104959B (en) Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
HUT66971A (en) 4-amino-naphthyridine derivatives pharmaceutical compositions containing the same and process for the production of thereof
ATE170530T1 (de) Thiazolidinderivate, ihre herstellung und medikamente, die sie enthalten
PT1270570E (pt) Composto de amida e sua utilizacao
PT649846E (pt) Derivados da galantamina processo para a sua preparacao e sua utilizacao como medicamentos
ATE140450T1 (de) Neue n-benzoylprolin-derivate, verfahren zur herstellung und diese enthaltende arzneimittel
MY132077A (en) Use of n-substituted phenothiazines for the production of medicaments, novel substances and a process for their preparation
DK0553778T3 (da) Asymmetrisk hydrogenering
CA2450274A1 (en) Benzoxazepine derivatives and their use as ampa receptor stimulators
DE59408453D1 (de) Pyrido-pyrimidindione, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES8609333A1 (es) Un procedimiento para la preparacion de un compuesto
FR2413362A2 (fr) Nouveaux antidotes de la famille des dichloracetamides
DE69322218D1 (de) Heteroarenylpiperazine, Verfahren zu ihrer Herstellung und ihre Anwendung als Medikamente
GR3015592T3 (en) Pharmaceuticals containing substituted cyclohex-2-en-1-yl-amine derivatives and their use in combatting diseases.
ES8103082A1 (es) Procedimiento de preparacion de nuevos derivados pirido (3,4-e)-as-triazinos acilados y de sus sales de acicion aci-da de los mismos
TNSN99235A1 (fr) Derives de 3 -azabicyclo [3,1,0] hexane nouveaux, procede pour leur preparation et compositions les contenant
PL300155A1 (en) Method of obtaining 3-amino pyroles non-substituted at their 1 position
ATE133953T1 (de) Hexahydro-1h-chino(4,3,2-ef>(1,4>benzoxazepine und verwandte verbindungen und zwischenprodukte zur herstellung und verwendung als arzneimittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee